1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Parnell Pharmaceuticals Holdings Ltd

Parnell Pharmaceuticals Holdings Ltd

PARNF
Parnell Pharmaceuticals Holdings LtdUS flagOther OTC
0.08
USD
-0.08
- -
1.68MMarket Cap
Parnell Pharmaceuticals Holdings Ltd
PARNF
(Other OTC)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2013
2014
2014
2015
2016
2017
2018
FRC
1.68
1.56
0.88
1.27
1.3
1.5
1.2
1.05
1.47
Revenue per Share
0.01
-0.46
-0.26
-2.25
-2.31
-1.03
-1.37
-1.27
0.01
Basic EPS, GAAP
0.07
-0.79
-0.45
-1.74
-0.26
-1.96
-1.09
-0.24
-0.24
Free Cash Flow per Basic Share
0.09
0.09
0.05
- -
- -
- -
- -
- -
- -
Dividend per Share
0.82
-0.14
- -
-2.39
-2.64
1.64
0.52
-0.82
-0.82
Book Value per Share
-0.23
-0.93
- -
3.46
2.86
0.28
-0.67
-1.29
-1.75
Tangible Book Value per Share
8
8
13
8
8
13
16
18
18
Basic Weighted Avg Shares
13
12
12
10
10
20
19
19
27
Sales/Revenue/Turnover
27.24
6.1
6.1
-58.28
-58.28
-62.58
-93.33
-54.32
12.88
Operating Margin (%)
1
2
2
1
1
1
3
8
3
Depreciation Expense
- -
-3
-3
-17
-17
-14
-22
-23
- -
Net Income, GAAP
89.95
- -
- -
- -
- -
- -
- -
- -
61.54
Effective Tax Rate (%)
0.53
-29.62
-29.62
-177.04
-177.04
-69.05
-113.87
-120.92
0.49
Profit Margin (%)
1
-14
- -
16
10
7
8
-1
3
Working Capital
12
4
- -
- -
- -
14
30
32
45
LT Debt
7
2
- -
37
34
20
8
-11
-19
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
5.55
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
11.85
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-144.56
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-56.97%
63.72%
Free Cash Flow
- -
211.46%
-0.3%
Net Income, GAAP
- -
- -
-100.56%
Sales/Revenue/Turnover
- -
- -
38.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
5
7
- -
19
2017
- -
- -
- -
- -
19
2018
- -
- -
- -
- -
27

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
-1.37
2017
- -
- -
- -
- -
-1.27
2018
- -
- -
- -
- -
0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Syncom Formulations (India) Limited (SYNCOMF.BO)
Teyi Pharmaceutical Group Co.,Ltd (002728.SZ)
Medicure Inc. (MPH.V)
Invion Limited (IVIXF)
Bajaj HealthCare Limited (BAJAJHCARE.BO)
Biofrontera AG (BFAGY)
Business
Parnell Pharmaceuticals Holdings Ltd (PARNF) is a fully integrated veterinary pharmaceutical company that develops, manufactures, and commercializes animal health solutions for companion animals, production animals, and performance animals. The company offers a portfolio of core products including reproductive hormone therapies such as estroPLAN and GONAbreed for dairy and beef cattle breeding programs; osteoarthritis treatments like Zydax for dogs and horses and Glyde nutraceuticals for canine osteoarthritis; respiratory disease solutions such as RESPIRmycin for bovine respiratory disease; anesthesia and sedation products including PropofolVet Multidose (generic propofol injectable emulsion), Parnell Brand Dexmedetomidine Hydrochloride Injection, and CONTRASED (atipamezole hydrochloride); anti-inflammatory injectables like Tergive (carprofen); and digital platforms such as mySYNCH for herd fertility management and analytics. It operates through segments encompassing Companion Animal, Production Animal U.S., Production Animal Rest of World, and Manufacturing Operations, with manufacturing in FDA- and EMA-accredited sterile facilities. Parnell markets its products in 14 countries across North America, Latin America, Europe, Asia, the Middle East, Africa, Australia, and New Zealand, targeting veterinarians, livestock producers, and pet care professionals. Founded in 2009 and headquartered in Alexandria, New South Wales, Australia, the company maintains key operations including a U.S. presence in Overland Park, Kansas. In recent developments, Parnell launched PropofolVet Multidose in January 2025 as the first generic propofol injectable emulsion for canine anesthesia; introduced a Veterinary Certificate program in Anesthesia and Sedation on January 21, 2025; added two new sedation products to its pet care line in May 2024; welcomed Dr. Chelsie Estey as Vice President of U.S. Pet Care in March 2024; and launched RESPIRmycin in January 2023. The company faces a pending acquisition proposal by RCBC BidCo Pty Ltd announced on November 29, 2024, with an expected completion by March 19, 2025, subject to extension; earlier, DW Healthcare Partners invested in 2021 following a tender offer.

Company News

APIChat

  • defenseworld.net

    Head to Head Comparison: Parnell Pharmaceuticals (OTCMKTS:PARNF) and Assembly Biosciences (NASDAQ:ASMB)